Key objectives include:
• Development of ECM-based bioinks optimized for tumor tissue engineering.
• Fabrication of 3D bioprinted tumor models that replicate in vivo-like conditions.
• Implementation of high-throughput drug screening methods for chemotherapy, immunotherapy, and targeted therapies.
• Integration with organ-on-a-chip technology to model tumor metastasis and drug responses.
Advantages and innovation
Traditional 2D cell cultures and animal models fail to accurately replicate the complex tumor microenvironment, leading to low translatability of preclinical drug testing results. Extracellular Matrix (ECM)-supported 3D bioprinting offers a more physiologically relevant alternative, allowing for the recreation of the tumor microenvironment, cellular interactions, and drug resistance mechanisms in a laboratory setting.
Technical Specification or Expertise Sought
The company is looking for spanish profit organisations who can take part as a project partner for 1-2 of following tasks:
• Development of ECM-based bioinks optimized for tumor tissue engineering.
• Fabrication of 3D bioprinted tumor models that replicate in vivo-like conditions.
• Implementation of high-throughput drug screening methods for chemotherapy, immunotherapy, and targeted therapies.
• Integration with organ-on-a-chip technology to model tumor metastasis and drug responses.

Framework program
Eureka
Call title and identifier
Türkiye and Spain call for R and D projects
Submission and evaluation scheme
Anticipated project budget
Coordinator required
No
Deadline for EoI 18 Apr 2025
Deadline of the call 24 Apr 2025